July 01, 2014
The Federal Circuit on Tuesday affirmed a lower court's ruling that two antibody patents that AbbVie Inc. accused Johnson & Johnson unit Janssen Biotech Inc.'s psoriasis treatment Stelara of infringing are invalid for lacking an adequate written description.
March 06, 2014
AbbVie Deutschland GmbH & Co. urged a Federal Circuit panel on Thursday to resurrect two of its antibody patents, alleging that "presumptively prejudicial" jury instructions doomed its infringement suit against a Johnson & Johnson subsidiary.